Insights
At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.
France to Adopt a Market Access Pathway Like the German System
France’s Health Innovation 2030 Plan Proposes to Adopt a Market Access Pathway Like the German System to Accelerate Patient Access to Innovative Medicines – What Changes Can Be Expected?
Rare Disease Day 2021: UK Roadmap to Improving Care for Rare Disease Patients
Earlier this year, the UK government announced the Rare Diseases Framework, outlining strategy to improve the delivery of care to the 3.5 million people living within the four nations of the UK with a rare disorder.
Unpacking the biotech sector: What sets this sector apart and what are the challenges
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.
How are payers adapting to the ATMP revolution?
Our CEO Herve Lillu recently led a discussion on this topic at the 2020 World Pharma pricing, Evidence, and Market Access Congress. Before we get
Four Market Access Measures Triggered by COVID-19 That Are Here To Stay
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.
Reflections on The Initial Impact of COVID-19 on Global Market Access Activities
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
How Payers in the US & Europe are adapting to the ATMP revolution
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
Drug R&D Public Funding – The Next Level Of Price Transparency Policies?
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
Tackling Rising Drug Costs in the US: Is ERP an Option?
Rising drug prices in the US are hot topic. Inbeeo takes a look at the recent drug pricing proposal by the Democrats suggesting the use of ERP.
4 Take-Away Messages From The Zolgensma® Pricing Storm
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
Decoding the data: Analytics of Drug Pricing Tweets
Inbeeo’s analysis of 2018 drug pricing tweets using NLP machine learning techniques highlight how emotive the issue of pharmaceutical pricing really is.
Four Definitions of Value-Based Pricing and Counting
What is Value-Based Pricing? It’s pricing based on value! Or is it? Let us try to define what it is once and for all.
In France, the value equation may change (a little)
France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
Six Drugs that Cost a Medicare Part D Beneficiary more than $10,000 a Year
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
The Dust Never Settled after Drug Pricing 9/22
The event that made people pay attention to how prescription drugs are being priced
Why I Prefer a Value-Based Healthcare Mayhem over the Status Quo
The value-denial syndrome used to be broadly shared between payers and the industry, and now they both seem to come to the same realization that value-based pricing is the only way. Easier said than done, but that’s a start.
Healthcare Appraisal: The Evolution of Value Based Healthcare
The Health Foundation and ICHOM are among the many stakeholders calling for an evolution of how we look at value in healthcare. Here are four trends emerging from their pledge.
Ask Not What Payers Can Do for You – Ask What You Can Do for Payers
Five tips worth keeping mind when planning for market access. An infographic.
Three Reasons Why Value Definition Is The Ultimate Challenge for Pharma
I have learned the hard way that defining the value of a pharmaceutical innovation is not as easy as “Bob’s your uncle”.
Care Affordability Index or How to Go Beyond the “# of Lives Covered” Metric
A Care Affordability Index could constitute a way more informative measure of patient-access performance than the binary “number of lives covered”. And it is not that complicated to implement. A post for dashboard lovers.
Drug Pricing – Feeling the Squeeze
Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.
Pharma Payers: Three Things They Want (Beyond Low Prices)
Making sure your new product brings no bad budgetary news, clearly telling its value story, and pricing it fairly will help you convince your payer audience to fund it.
Three Reasons not to Use R&D Costs to Justify Drug Prices
As pharma industry leaders continue to feel a pressuring demand from all parts to justify the price of their innovative products, there is one trap everyone seems to be happily falling into – the cost of Research and Development.
